Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder in Pulmonary Arterial Hypertension
2023-505539-11-00Phase 3Authorised
- Sponsor
- Insmed Incorporated
- Start
- Sep 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 17
01
Overview
Phase 3, open-label, single-arm trial of treprostinil palmitil in pulmonary arterial hypertension (PAH), sponsored by Insmed Incorporated. Primary endpoint: Frequency and severity of treatment-emergent adverse events (TEAEs). Planned start Sep 2024; status: authorised.
02
Drugs
treprostinil palmitil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2023-505539-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505539-11-00.